NCT06375109View on ClinicalTrials.gov

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

April 15, 2027

Study Completion Date

April 15, 2029

Conditions

Limited-stage Small-cell Lung Cancer

Interventions

DRUG

Tislelizumab

administered via Intravenous (IV) injection

DRUG

Carboplatin injection

administered via IV injection

DRUG

Cisplatin injection

administered via IV injection

DRUG

Etoposide injection

administered via IV injection

All Listed Sponsors

lead

Beijing Chest Hospital, Capital Medical University

OTHER

NCT06375109 - PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC | Biotech Hunter | Biotech Hunter